Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.31 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.31 |
| ▸ | CTRC | Q99895 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2329649 | 0.78 | KDM4E (0.36) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL5405213 | 0.75 | CA2 (0.33) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL462653 | 0.75 | HTR1A (0.36) | HTR1ADRD2HTR2AHTR7HTR6 | |
| Hydrochloric Acid SCHEMBL5395885 | 0.73 | HTR1A (0.36) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL5395789 | 0.70 | ADORA2A (0.40) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL826916 | 0.60 | — | — | |
| Hydrogen Sulfide SCHEMBL3280224 | 0.57 | TYR (0.42) | CTRC | |
| SCHEMBL983361 | 0.57 | CTRC (0.41) | KDM4EALDH1A1GAACTRC | |
| SCHEMBL21675106 | 0.56 | KIF11 (0.43) | — | |
| SCHEMBL13995371 | 0.56 | BRD4 (0.44) | ALDH1A1CTRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012032545-A1 | PROCESSES FOR PREPARING DRONEDARONE AND ITS INTERMEDIATES | CADILA HEALTHCARE LIMITED (IN) | 2012-03-15 | — | — | WO | disclosed |
| US-7312345-B2 | Process for the preparation of dronedarone | ISP INVESTMENTS INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20050049302-A1 | Process for the preparation of dronedarone | ISP INVESTMENTS LLC | 2005-03-03 | — | — | US | disclosed |
| WO-2003040120-A1 | PROCESS FOR THE PREPARATION OF DRONEDARONE | ISP INVESTMENTS INC. (US) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049302-A1 | Process for the preparation of dronedarone | CACNA1C, CACNA1A, KCNH1 | HTR1A 2491/4885DRD2 500/4885HTR2A 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.